A). GSEA was performed on the same chemotherapy treated
and untreated human and mouse tumors as in Fig.
1 using a 28 gene panel shown to predict response to ICI48. B) One
MMTV-Wnt1 tumor (5560) was transplanted in parallel into
C57BL/6j mice. When tumors became ~200mm3, mice were randomized to
four groups: 1) IgG alone, n=4 tumors (black dashed lines, left graph); 2)
αPD-L1 alone, n=4 tumors (pink dashed lines, left graph), 3) doxorubicin
treatment followed by IgG, n=5 tumors (black lines, right graph); 4) doxorubicin
treatment followed by αPD-L1, n=7 tumors (pink lines, right graph).
Doxorubicin treatments are indicated in the graph by orange arrowheads,
IgG/PD-L1 treatments are indicated by green triangles. C)
MMTV-Wnt1 tumors 3642 (top) or 5581 (bottom) were
transplanted in parallel into C57BL/6j mice. When tumors became
~200mm3, mice were randomized to 8 treatment groups: 1) IgG+IgG
alone (3642 n=4, 5581 n=4 tumors) (black dashed lines); 2) αPD-1+IgG
alone (3642 n=6, 5581 n=6 tumors) (green dashed lines); 3) IgG+αCTLA4
alone (3642 n=5, 5581 n=3 tumors) (blue dashed lines); 4)
αPD-1+αCTLA4 alone (3642 n=6, 5581 n=6 tumors) (red dashed line);
5) doxorubicin treatment followed by IgG+IgG (3642 n=9, 5581 n=5 tumors) (black
solid lines); 6) doxorubicin treatment followed by αPD-1+IgG (3642 n=12,
5581 n=14 tumors) (green lines); 7) doxorubicin treatment followed by
IgG+αCTLA4 (3642 n=13, 5581 n=15 tumors) (blue solid lines); 8)
doxorubicin treatment followed by αPD-1+αCTLA4 (3642 n=14, 5581
n=15 tumors). The 5 doxorubicin treatment days are indicated in the graphs by
orange arrowheads, the 3 IgG/αPD-L1/αCTLA4 treatment days are
indicated purple triangles. Tables showing mean percent tumor volume lost and
days to relapse after indicated treatments are provided for each transplant
experiment. SEM is provided for each value. Statistical significance was
determined using two-tailed Student’s T-test for comparisons of two
groups (B), and one-way ANOVA with Tukey’s posttest for
comparisons of three or more groups (C-D).